Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 10/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.56 |
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
| ▸ | HTR2B | P41595 | 3/20 | 0.56 |
| ▸ | NR2E1 | Q9Y466 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HTR2C | P28335 | 3/20 | 0.56 |
| ▸ | HTR6 | P50406 | 3/20 | 0.56 |
| ▸ | HTR1A | P08908 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | SCN1A | P35498 | 2/20 | 0.56 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indenolol SCHEMBL79021 | 1.00 | ADRB2 (0.56) | ADRB2ADRB1ADRB3SIGMAR1CYP1A2 | |
| Indenolol SCHEMBL349114 | 0.99 | ADRB2 (0.57) | ADRB2ADRB1ADRB3SIGMAR1CYP1A2 | |
| Indenolol SCHEMBL349116 | 0.99 | ADRB2 (0.57) | ADRB2ADRB1ADRB3SIGMAR1CYP1A2 | |
| Indenolol SCHEMBL1650473 | 0.98 | ADRB2 (0.54) | ADRB2ADRB1ADRB3SIGMAR1CYP1A2 | |
| SCHEMBL11631654 | 0.93 | ADRB2 (0.47) | ADRB2ADRB1ADRB3SIGMAR1CYP1A2 | |
| SCHEMBL11656702 | 0.89 | ADRB2 (0.44) | ADRB2ADRB1ADRB3SIGMAR1CYP1A2 | |
| Idropranolol SCHEMBL1255318 | 0.88 | ADRB1 (0.54) | ADRB2ADRB1ADRB3SIGMAR1CYP1A2 | |
| Indenolol SCHEMBL11666579 | 0.86 | ADRB2 (0.48) | ADRB2ADRB1ADRB3SIGMAR1CYP1A2 | |
| SCHEMBL11754160 | 0.85 | ALOX15 (0.41) | ADRB2ADRB1ADRB3SIGMAR1CYP1A2 | |
| Hydrochloric Acid SCHEMBL11659927 | 0.84 | ADRB2 (0.46) | ADRB2ADRB1ADRB3SIGMAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4399 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| US-10788500-B2 | IL1RL-1 as a cardiovascular disease marker and therapeutic target | BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 2020-09-29 | — | — | US | claimed |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| EP-3072526-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | ONCOMED PHARM INC (US) | 2018-09-26 | — | — | EP | claimed |
| US-20180217160-A1 | IL1RL-1 as a Cardiovascular Disease Marker and Therapeutic Target | THE BRIGHAM & WOMEN'S HOSPITAL, INC. | 2018-08-02 | — | — | US | claimed |
| EP-3072978-B1 | 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER | BRIGHAM & WOMENS HOSPITAL INC (US) | 2018-07-11 | — | — | EP | claimed |
| US-9982042-B2 | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent | ONCOMED PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | claimed |
| EP-0163237-A2 | Di- and tri-peptidal renin inhibitors | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | claimed |
| EP-0157409-A2 | Renin inhibitors containing 2-substituted statine | MERCK & CO. INC. (US) | 1985-10-09 | — | — | EP | claimed |
| EP-0156318-A2 | C-terminal amide cyclic renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0156322-A2 | Renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0153200-A2 | Medicinal patch | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1985-08-28 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| EP-0105996-A1 | Ophthalmic compositions for treating elevated intraocular pressure | MERCK & CO. INC. (US) | 1984-04-25 | — | — | EP | claimed |
| US-4303637-A | Medication indicated for ocular hypertension | ALZA CORPORATION (US) | 1981-12-01 | — | — | US | claimed |
| EP-0037622-A2 | Drug delivery insert for controlled ocular therapy | ALZA CORPORATION (US) | 1981-10-14 | — | — | EP | claimed |
| US-4281654-A | Drug delivery system for controlled ocular therapy | ALZA CORPORATION (US) | 1981-08-04 | — | — | US | claimed |